Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Nektar Therapeutics ( (NKTR) ) has issued an announcement.
On May 23, 2025, Nektar Therapeutics‘ stockholders approved a reverse stock split, which was later confirmed by the Board to be a one-for-fifteen split. This adjustment will take effect on June 8, 2025, with trading on a split-adjusted basis commencing on June 9, 2025, under the existing symbol ‘NKTR’. The reverse stock split aims to consolidate shares, potentially impacting the company’s stock market performance and shareholder value.
The most recent analyst rating on (NKTR) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
Nektar Therapeutics’ overall stock score reflects the company’s substantial financial challenges, including declining revenues and high leverage. Technical analysis indicates potential resistance, while valuation metrics are unattractive due to a negative P/E ratio. Despite some positive developments in their pipeline and a strong cash position, significant risks remain, including litigation and non-cash losses.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics operates in the biotechnology industry, focusing on developing innovative drug candidates for various medical needs.
Average Trading Volume: 2,081,366
Technical Sentiment Signal: Sell
Current Market Cap: $148.2M
See more data about NKTR stock on TipRanks’ Stock Analysis page.